Clinical and economic evaluation of the impact of methicillin resistance on prosthetic joint infections
Öz
Purpose: Prosthetic joint infection (PJI) is unfortunately a costly process. In this study, we aimed to examine the effect of methicillin resistance on the cost of PJI compared to susceptible patients.
Materials and Methods: Patients who underwent primary hip or knee arthroplasty in our center between January 2012 and December 2021 and were diagnosed with staphylococcal PJI were included in this retrospective design study. Expenses incurred during hospitalization were divided into categories. Each expense was converted to dollars ($) at the annual average exchange rate.
Results: A total of 55 patients were included in the study. There were 31 and 24 patients in the methicillin-resistant and susceptible groups, respectively. The methicillin-resistant group was significantly older than the susceptible group, other characteristics were similar. The cost in the methicillin-resistant group was $2055.7 ($676.0-$12620.0) and in the susceptible group was $1643.9 ($707.8-$10834.8). There was a statistically significant difference between the two groups in terms of surgical costs, antibiotic costs, blood center costs and radiology costs.
Conclusion: According to our study, the treatment cost of methicillin-resistant staphylococcus PJI was 1.3 times higher than that of methicillin-susceptible.
Anahtar Kelimeler
Primary arthroplasty, antimicrobial resistance, health expenditure, economic burden, cost
Kaynakça
- Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780-5.
- Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645-54.
- Urkmez FY, Yildiz F, Doganay M et al. Analysis of the cost of periprosthetic joint infections after total knee and hip arthroplasty and the effect of revision methods on the cost. Chir Narzadow Ruchu Ortop Pol. 2021;86:109-14.
- Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;27:61-5.e1.
- ECDC, EFSA Panel on Biological Hazards (BIOHAZ), EMA Committee for Medicinal Products for Veterinary Use (CVMP). ECDC, EFSA and EMA joint scientific opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animals. EFSA J. 2017;15:e05017.
- Barberán J, Aguilar L, Carroquino G, Giménez MJ, Sánchez B, Martínez D, Prieto J et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med. 2006;119:993.e7-10.
- Aggarwal VK, Bakhshi H, Ecker NU, Parvizi J, Gehrke T, Kendoff D. Organism profile in periprosthetic joint infection: pathogens differ at two arthroplasty infection referral centers in Europe and in the United States. J Knee Surg. 2014;27:399-406.
- Parvizi J, Ghanem E, Azzam K, Davis E, Jaberi F, Hozack W. Periprosthetic infection: are current treatment strategies adequate? Acta Orthop Belg. 2008;74:793-800.
- Carrega G, Casalino-Finocchio G, Cavagnaro L, Felli L, Riccio G, Burastero G. Long-term outcome of prosthetic joint infections treated with two-stage revision. Acta Orthop Belg. 2020;86:10-6.
- Viswanathan V, Pendsey S, Radhakrishnan C, Rege TD, Ahdal J, Jain R. Methicillin-resistant Staphylococcus aureus in diabetic foot infection in India: a growing menace. Int J Low Extrem Wounds. 2019;18:236-46.
